Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Winkel, Per ; Jakobsen, Janus Christian ; Hilden, Jørgen ; Jensen, Gorm Boje ; Kjøller, Erik ; Sajadieh, Ahmad ; Kastrup, Jens ; Kolmos, Hans Jørn ; Iversen, Kasper Karmark ; Bjerre, Mette ; Larsson, Anders ; Ärnlöv, Johan ; Gluud, Christian. / Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial. I: BMJ Open. 2020 ; Bind 10, Nr. 8.

Bibtex

@article{0b38f7e1fba64c87bde5b9b849150e70,
title = "Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial",
abstract = "Objective To assess if 12 novel circulating biomarkers, when added to standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease. Design The patients participated as placebo receiving patients in the randomised clarithromycin for patients with stable coronary artery disease (CLARICOR) trial at a random time in their disease trajectory. Setting Five Copenhagen University cardiology departments and a coordinating centre. Participants 1998 participants with stable coronary artery disease. Outcomes Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease and death. Results When only standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin-S) were not associated (p≥0.01) with the outcomes, not even as single predictors. Adding the remaining 10 biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumour necrosis factor receptor 1 and 2; pregnancy-associated plasma protein A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%. Conclusion When standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary artery disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by <1.5%. Trial registration number NCT00121550.",
keywords = "Biomarker, Cardiology, Coronary heart disease",
author = "Per Winkel and Jakobsen, {Janus Christian} and J{\o}rgen Hilden and Jensen, {Gorm Boje} and Erik Kj{\o}ller and Ahmad Sajadieh and Jens Kastrup and Kolmos, {Hans J{\o}rn} and Iversen, {Kasper Karmark} and Mette Bjerre and Anders Larsson and Johan {\"A}rnl{\"o}v and Christian Gluud",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = aug,
day = "20",
doi = "10.1136/bmjopen-2019-033720",
language = "English",
volume = "10",
journal = "BMJ Paediatrics Open ",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "8",

}

RIS

TY - JOUR

T1 - Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial

AU - Winkel, Per

AU - Jakobsen, Janus Christian

AU - Hilden, Jørgen

AU - Jensen, Gorm Boje

AU - Kjøller, Erik

AU - Sajadieh, Ahmad

AU - Kastrup, Jens

AU - Kolmos, Hans Jørn

AU - Iversen, Kasper Karmark

AU - Bjerre, Mette

AU - Larsson, Anders

AU - Ärnlöv, Johan

AU - Gluud, Christian

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/8/20

Y1 - 2020/8/20

N2 - Objective To assess if 12 novel circulating biomarkers, when added to standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease. Design The patients participated as placebo receiving patients in the randomised clarithromycin for patients with stable coronary artery disease (CLARICOR) trial at a random time in their disease trajectory. Setting Five Copenhagen University cardiology departments and a coordinating centre. Participants 1998 participants with stable coronary artery disease. Outcomes Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease and death. Results When only standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin-S) were not associated (p≥0.01) with the outcomes, not even as single predictors. Adding the remaining 10 biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumour necrosis factor receptor 1 and 2; pregnancy-associated plasma protein A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%. Conclusion When standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary artery disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by <1.5%. Trial registration number NCT00121550.

AB - Objective To assess if 12 novel circulating biomarkers, when added to standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease. Design The patients participated as placebo receiving patients in the randomised clarithromycin for patients with stable coronary artery disease (CLARICOR) trial at a random time in their disease trajectory. Setting Five Copenhagen University cardiology departments and a coordinating centre. Participants 1998 participants with stable coronary artery disease. Outcomes Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease and death. Results When only standard predictors' were included, 83.4% of all-cause death predictions and 68.4% of composite outcome predictions were correct. Log(calprotectin) and log(cathepsin-S) were not associated (p≥0.01) with the outcomes, not even as single predictors. Adding the remaining 10 biomarkers (high-sensitive assay cardiac troponin T; neutrophil gelatinase-associated lipocalin; osteoprotegerin; N-terminal pro-B-type natriuretic peptide; tumour necrosis factor receptor 1 and 2; pregnancy-associated plasma protein A; endostatin; YKL40; cathepsin-B), which were all individually significantly associated with the prediction of the two outcomes, increased the figures to 84.7% and 69.7%. Conclusion When standard predictors' routinely available in general practices are used for risk assessment in consecutively sampled patients with stable coronary artery disease, the addition of 10 novel biomarkers to the prediction model improved the correct prediction of all-cause death and the composite outcome by <1.5%. Trial registration number NCT00121550.

KW - Biomarker

KW - Cardiology

KW - Coronary heart disease

UR - http://www.scopus.com/inward/record.url?scp=85089769818&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-033720

DO - 10.1136/bmjopen-2019-033720

M3 - Journal article

C2 - 32819979

VL - 10

JO - BMJ Paediatrics Open

JF - BMJ Paediatrics Open

SN - 2044-6055

IS - 8

M1 - e033720

ER -

ID: 60727001